‡ The five patients who initiated omalizumab but who were categorized as not having allergic rhinitis all had IgE levels within the accepted range for omalizumab dosing and a documented history of perennial rhinitis; however, we did not see the objective evidence of testing for perennial allergens. This evidence concerns the gene IGHE and allergic rhinitis.